Melvin LK Chua: A meeting not to be missed and will only grow from strength to strength
Melvin LK Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore, shared a post on X:
“My take on ASCOBT24 and why this is a meeting not to be missed and will only grow from strength to strength!
ASCO Breakthrough Will Explore Artificial Intelligence, Novel Therapeutics, and Health Equity.”
Quoting Melvin LK Chua’s post, Lilian Siu commented:
“Looking forward to seeing everyone soon in Yokohama!”
View the podcast attached to the post.
Source: Melvin LK Chua/X and Lilian Siu/X
Lillian Siu is a Professor of Medicine at the University of Toronto (Canada), senior medical oncologist, Director of the Phase I Program, Co-Director of the Bras and Family Drug Development Program and the Clinical Lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. She holds the BMO Chair in Precision Genomics (2016-2026). Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO), was a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016), and currently serves on the AACR Board of Directors. She is a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology.